Skip to main content
. 2021 Sep 2;13(4):424–430. doi: 10.4103/UA.UA_139_20

Figure 1.

Figure 1

Estimated probability with Kaplan Meier analysis of recurrence-free survival in patients adequately treated with adjuvant HIVEC with mitomycin (black) and Intravesical BCG (Moscow-I strain) (dotted line) for Nonmuscle Invasive Bladder Cancer (HIVEC: Hyperthermic Intra-VEsical Chemotherapy, BCG: Bacillus Calmette-Guerin)